Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm

DALLAS, July 27 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP - News) announced today that its European partner, SpePharm, has commenced commercial launch of MuGard in Norway. This follows previous commercial launches in the UK, Germany, Italy and Greece. Under a license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory approval and commercialization in the 27 countries of Europe. SpePharm plans to launch MuGard throughout Europe over the next 12 months, with direct launches planned in France, Spain and the Benelux countries, and launches through local distributors in Central and Eastern Europe. The license agreement includes royalties on net sales to Access.